Bionano Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22 Setembro 2023 - 5:05PM
Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that on
September 18, 2023, the Compensation Committee of the Company’s
Board of Directors (the “Compensation Committee”) granted an
inducement award consisting of a non-qualified stock option to
purchase 106,000 shares of common stock to Gülsen Kama, the
Company’s new Chief Financial Officer, under the Company’s 2020
Inducement Plan, as amended. The Compensation Committee approved
the award as an inducement material to the new employee’s
employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option has an exercise price per share
equal to $3.00 per share, the Company’s closing trading price on
September 18, 2023, and will vest over four years, with 25% of the
underlying shares vesting on the one-year anniversary of the grant
date and the balance of the underlying shares vesting monthly
thereafter over 36 months, subject to Ms. Kama’s continued service
relationship with the Company through the applicable vesting dates.
The award is subject to the terms and conditions of the Company’s
2020 Inducement Plan, as amended, and the terms and conditions of
the applicable award agreement covering the grant.
About Bionano
Bionano is a provider of genome analysis
solutions that can enable researchers and clinicians to reveal
answers to challenging questions in biology and medicine. The
Company’s mission is to transform the way the world sees the genome
through OGM solutions, diagnostic services and software. The
Company offers OGM solutions for applications across basic,
translational and clinical research. Through its Lineagen, Inc.
d/b/a Bionano Laboratories business, the Company also provides
diagnostic testing for patients with clinical presentations
consistent with autism spectrum disorder and other
neurodevelopmental disabilities. The Company also offers an
industry-leading, platform-agnostic software solution, which
integrates next-generation sequencing and microarray data designed
to provide analysis, visualization, interpretation and reporting of
copy number variants, single-nucleotide variants and absence of
heterozygosity across the genome in one consolidated view. The
Company additionally offers nucleic acid extraction and
purification solutions using proprietary
isotachophoresistechnology. For more information, visit
www.bionano.com, www.bionanolaboratories.com or
www.purigenbio.com.
Unless specifically noted otherwise, Bionano’s
OGM products are for research use only and not for use in
diagnostic procedures.
CONTACTS
Company Contact:
Erik Holmlin, CEOBionano Genomics, Inc.+1 (858)
888-7610eholmlin@bionano.com
Investor Relations:
David HolmesGilmartin Group+1 (858)
888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Bionano Genomics (NASDAQ:BNGO)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024